Table: Towa Pharmaceutical -6-MTH group results
Nov 9 (Reuters)-
Towa Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Sep 30, 2015 Sep 30, 2014 Mar 31, 2016
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 39.16 33.47 82.00
(+17.0 pct) (+17.2 pct) (+14.7 pct)
Operating 5.52 4.18 11.50
(+32.0 pct) (+34.1 pct) (+3.6 pct)
Recurring 5.61 5.55 11.50
(+1.1 pct) (+76.7 pct) (-25.5 pct)
Net 4.01 4.07 8.20
(-1.3 pct) (+101.4 pct) (-26.2 pct)
EPS 239.07 yen 239.40 yen 493.60 yen
EPS Diluted 229.96 yen
Ann Div 95.00 yen 95.00 yen
-Q2 div 47.50 yen 37.50 yen
-Q4 div 57.50 yen 47.50 yen
NOTE - Towa Pharmaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4553.T
((Tokyo Headline News Desk +813 6441 1812))
Recent news on TOWA PHARMACEUTICAL
See all newsTable: Towa Pharmaceutical -Q1 group results
Notice Of Acquisition Of Shares Of Tanabe Pharma Factory And Transfer Of Manufacturing And Marketing Approvals
Brief: Breckenridge Launches Tofacitinib Tablets, Generic Equivalent Of Xeljanz By Pfizer
Table: Towa Pharmaceutical -2025/26 parent results
Table: Towa Pharmaceutical -2025/26 group results